Changing trends in proportional incidence and net survival of screened and nonscreened breast cancers among women in England

Haiyan Wu, MS,¹ Kwok Wong, PhD,² Shou-En Lu, PhD,^{3,4} John Broggio, PhD,² Lanjing Zhang, MD, FRCPath^{3,5-7}

¹Department of Clinical Epidemiology, Institute of Health Informatics, Faculty of Population Health Sciences, University College London, London, UK; ²National Cancer Registration and Analysis Service, Public Health England, Birmingham B3 2PW, UK; ³Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; ⁴Department of Biostatistics, School of Public Health, Rutgers University, Piscataway, NJ; ⁵Department of Pathology, Princeton Medical Center, Plainsboro, NJ; ⁶Department of Biological Sciences, Rutgers University, Newark, NJ; ⁷Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ.

Correspondence: Lanjing Zhang, MD, FRCPath, Department of Pathology, Princeton Medical Center, 1 Plainsboro Rd, Plainsboro, NJ 08536, USA. email: lanjing.zhang@rutgers.edu

Key words: Breast cancer, screening, net survival, trends, incidence

Word Count: 2266

Abstract (250 words)

Background: Uptake of breast cancer screening has been decreasing in England since 2007, and may increase proportional incidence of nonscreened cancers. However, recent trends in proportional incidence and net-survivals of screened and nonscreened breast cancers are unclear.

Methods: We extracted population-based proportional incidence and age-standardized 5-year net-survivals from Public Health England, for English women with invasive breast cancer diagnosed during 1995-2011 (linked to death certificates, followed through 2016). Piecewise log-linear models with change-point/joinpoint were used to estimate temporal trends. We conducted a quasi-experimental study to test the hypothesis that the trend-change year of proportional incidence coincided with that of 5-year net-survival.

Results: Among 254,063 women in England with invasive breast cancer diagnosed during 1995-2011, there was downward-to-upward trend-change in proportional incidence of nonscreened breast cancers (annual percent change[APC]=5.6 after 2007 versus APC=-3.5 before 2007, $P<0.001$) in diagnosis-year 2007, when steeper upward-trend in age-standardized 5-year net survival started (APC=5.7 after 2007/2008 versus APC=0.3 before 2007/2008, $P<0.001$). Net-survival difference of screened versus nonscreened cancers also significantly narrowed (18% in 2007/2008 versus 5% in 2011). Similar associations were found in all strata of race, cancer stage, grade and histology, except in Black patients or patients with stage I, stage III, or grade I cancer.

Conclusions: The downward-to-upward trend-change in proportional incidence of nonscreened breast cancers is associated with steeper upward-trend in age-standardized 5-year net survival among English women in recent years. Survival benefits of breast cancer screening appear decreasing in recent years. The data support reduction of breast cancer screening in some patients.

Introduction:

Cancer screening is adopted worldwide for breast cancer prevention and control.¹ The uptake of breast cancer screening has been decreasing among women in England since 2007, from 73.2% among women aged 50-70 years in 2007-2008 to 70.5% in 2017-2018.^{2,3} Given widely accepted benefits of cancer screening,^{4,5} the decrease in screening may increase the proportional incidence of nonscreened breast cancers and suppress improvement of their survivals. However, the long-term trends in proportional incidence of screened and nonscreened breast cancers are largely unknown, despite an overall upward trend of breast cancer incidence in England.^{6,7}

The benefits and harms of breast cancer screening are controversial, although benefits appear to outweigh harms.^{5,8-11} Thus, the recent decrease in uptakes of breast cancer screening in England may also link to different changes in breast cancer survival of nonscreened and screened patients. However, the trends in net survival of screened and nonscreened invasive breast cancers are unclear among women in England, while the overall net survivals have been increased in recent years.^{6,7} Therefore, using data from Public Health England, we estimated these 5-year net survival trends during 1995-2016. We also conducted a quasi-experimental study to examine whether the trend change in proportional incidence of nonscreened invasive breast cancers is associated with trend change in age-standardized 5-year net survival of these cancers among women in England. Subgroup analyses by cancer stage, histology, cancer grade and patient race were also performed. This quasi-experimental study may help better understand the benefits of breast cancer screening in recent years.

Methods:

We requested the aggregated data of proportional incidence and age-standardized 5-year net survival of invasive breast cancer by various factors, which were prepared for, calculated using Stata (version 15, StataCorp LLC, TX), and released by the National Cancer Registration and Analysis Service within Public Health England (PHE).^{6,12} The database has been used for studying breast, pediatric and colorectal cancers.¹³⁻¹⁵ The invasive breast cancer was classified according to the International Statistical Classification of Diseases 10th Revision (ICD-10) and by morphology and behavior codes in the International Classification of Diseases for Oncology, Second Edition (ICD-O-2). The net survival is a ratio calculated by dividing the overall/observed survival of cancer patients over that of the general population using the Pohar-Perme estimator.¹⁶ The net survival used here adjusts the survival of breast cancer patients with that of the general population using an updated, smoothed life table.¹⁷ Age-standardization was performed using the International Cancer Survival Standard age-weightings.¹⁸ We included all qualified invasive breast cancers (site and morphology. Primary site-labeled: breast) in England diagnosed during 1995-2011 (released in February 2019). The exclusion criteria included: Death certificate only, autopsy only, or alive with no survival time; Exclusion to match the expected survival table: age value not found in table, invalid year and values not found for other variables. Since we used this existing, de-identified, publicly available dataset, no Institutional Review Board (IRB) review was required.

We classified the cancer stage using a TNM-based staging system defined by Cancer Research UK.¹⁹ The cancer histology was classified and categorized using the International-Classification of Disease for Oncology (ICD-O)-2,²⁰ according to the pathology diagnosis in medical charts. We grouped the tumors into invasive ductal carcinoma (IDC, ICD-O-2 8500/3), invasive lobular carcinoma (ILC, ICD-O-2 8520/3), mixed invasive ductal and lobular carcinoma (MDLC, ICD-O-2 8522/3) and non-ductal non-lobular

carcinomas (all other codes) for the primary analyses. We stratified the proportional incidence and age-standardized 5-year net-survivals by diagnosis year, race, histology, cancer stage and cancer grade among women with screened or nonscreened breast cancer. We calculated proportional incidence using stratum's incident case number divided by the number of all strata's incident cases.

In the quasi-experimental study, we identified and compared the changing points of the trends in proportional incidence and age-standardized 5-year net survival, respectively, using piece-wise log-linear models of the Joinpoint program (Version 4.6.0.0., Statistical Research and Applications Branch, National Cancer Institute, Bethesda, MD).²¹ We employed the following setups for analyses: standard errors (provided) option for Heteroscedastic Errors Option (Weighted Least Squares); grid search method with 2 as the minimal number of observations from a joinpoint to either end of the data (excluding the first or last joinpoint if it falls on an observation) and the minimal number of observations between two joinpoints (excluding any joinpoint if it falls on an observation).^{21,22} The model selection for the best-fit joinpoint was based on permutation tests with overall significance level at 0.05. We also compared the trends/slopes among the strata using the pairwise comparison function of Joinpoint program.²² On very rare occasions (<1%), age-standardized net-survivals were unavailable due to missing data, and those data points would be omitted in the analysis. All *P* values were 2-sided, and would be considered statistically significant when <0.05.

Results:

Trends in the proportional incidence of invasive breast cancer among women in England diagnosed during 1995-2011

Among the 254,063 women in England with invasive breast cancer diagnosed during 1995-2011 (183,018 [72.0%] IDC, 30,323 [11.9%] ILC, 9,324 [3.7%] MDLC, and 31,398 [12.4%] others), 122,870 (48.8%) were screened cancers overall (**Table 1**). The proportional incidence of screened breast cancer (versus nonscreened) was significantly different by diagnosis year, race, histology, stage and tumor grade (**Table 1**). We found a joinpoint in the proportional incidence of nonscreened breast cancer in 2007, when the proportion of screened cancer increased from 37.3% to 57.0% during 1995-2007 (APC[95% Confidence interval, CI]=4.0 [3.1 to 5.0], $P<0.001$) but decreased from 57.0% to 47.6% afterward (APC [95% CI]=-5.3 [-8.2 to -2.3], $P=0.002$, **Table 2**). The same joinpoint of 2007 was also identified in the trend of proportional incidence of nonscreened breast cancer (**Figure**). The trends in proportional incidence of screened breast cancer too differed by histology, stage and cancer grade, but not race (**Table 2**).

Trends in the age-standardized 5-year net-survival of screened and nonscreened breast cancers diagnosed among women in England during 1995-2011 (followed through 2016)

The age-standardized 5-year net survival of screened cancer was higher than that of nonscreened cancer, while the difference was significantly decreasing for the cancers diagnosed during 2007-2011 (19% difference for cancers diagnosed in 1995 versus 18% and 5% for those diagnosed in 2007/2008 and 2011, respectively, $P_{parallelism}<0.001$, **Table 3**). There were upward trends in the age-standardized 5-year net-survival of screened and nonscreened breast cancers diagnosed among women in England, while a steeper upward trend was seen for the cancers diagnosed after 2007/2008 (2007 and 2008 had the same survivals, **Figure**). This joinpoint appeared to coincide with the joinpoint of proportional incidence of nonscreened breast cancer, and supports our hypothesis. For both screened and nonscreened breast cancers, the trends of age-standardized 5-year net-survival differed by race, histology, stage and tumor

grade (**Table 3**). Compared with screened breast cancers, nonscreened breast cancers also showed different trends in the age-standardized 5-year net-survival by these factors, although some strata did not show trend difference, such as White race and stage 2 cancer ($P_{parallelism}=0.454$ and 0.053 , respectively. **Table 3**).

Discussion

Among the 254,063 women in England with invasive breast cancer diagnosed during 1995-2011, the difference in age-standardized 5-year net survival of screened versus nonscreened cancers was significantly decreasing for the cancers diagnosed during 2007-2011. The downward-to-upward trend change in proportional incidence of nonscreened breast cancer in 2007 coincided with a steeper upward trend in age-standardized 5-year net survival of nonscreened invasive breast cancer, suggesting a possible association of the two trend changes. Similar associations were found in all strata of race, cancer stage, cancer grade and histology, except in Black patients or patients with stage I, stage III, or grade I cancer.

We here provide early evidence on the 16-year trends of proportional incidence of screened and nonscreened breast cancers among women in England. In contrast to our finding, a world-wide population study shows no decrease in incidence of advanced breast cancer following sustained implementation of breast cancer screening during 1980s-2000s, including no significant trends in Scotland.¹ That study may be influenced by the lack of piece-wise linear modelling recommended by CDC guidelines,^{23,24} no data after 2007 and the difference between Scotland and England. It also defines advanced breast cancer mainly by cancer size, whereas we used clinical cancer staging, which is more widely used and adopted by Public Health England.⁶ Proportional incidence used here is adjusted to

incidence of all breast cancers and in our view is more reliable than unadjusted incidence. We showed a downward trend in the proportional incidence of early-stage screened breast cancer since the beginning of the decrease in uptake of breast cancer screening in 2007. Thus, it is possible that the recent decrease in screening uptake is associated with decrease in proportional incidence of early-stage breast cancer and increase in that of late-stage breast cancer.

The quasi-experimental study reveals a novel association of the trend changes in proportional incidence of nonscreened breast cancer with the trend-changes in 5-year net survival of nonscreened breast cancer. Despite the increase in proportional incidence of advanced nonscreened breast cancers, our data show that a downward-to-upward trend change in proportional incidence of nonscreened breast cancer coincided with a steeper upward trend in net survival of nonscreened breast cancers after 2007. This finding is somewhat surprising, but consistent with an estimated 1-10% of overdiagnosis rate in the U.K.^{4,25} and an upward survival trend in England.^{7,26} In another word, breast cancer screening in England may not be as beneficial as reported before.^{9,10,27} More studies are needed to explain the novel association. Given the much higher rate of overdiagnosis (~30%),^{28,29} and decreasing screening rate in the U.S.,^{30,31} it is very interesting to investigate whether the decrease in breast cancer screening is associated with an upward trend in relative/net survival in the U.S.

We also explored the factors associated with the link between increasing proportional incidence of nonscreened breast cancers and their improving age-standardized 5-year net survival. First, we show a steeper upward trend in age-standardized 5-year net survival in all strata of race, cancer stage, grade and histology among patients with nonscreened breast cancer after 2007, except in some patients. Therefore, the overall increasing survivals of breast cancer, as reported before,^{7,26} appear disproportionately linked to the nonscreened breast cancers of advanced stage, higher grade and

common histologic types. Second, we found downward trends in age-standardized 5-year net survival of some screened cancers, which are grade I and other histologic types. The downward trend in these screened breast cancers is concerning and warrants more studies, but consistent with a worse overall survival of other/uncommon type of breast cancers in the U.S.³² Finally, patients with a black ethnical background in this study appeared not to have increasing proportional incidence of nonscreened breast cancer, nor (subsequent) steeper upward trend in net survival after 2007. However, the role of socioeconomic disparity/inequality in the screening uptake and survival of breast cancer remains controversial for English patients, including studies of supportive³³⁻³⁶ and undermined conclusions.^{37,38} More research is required to understand this role of socioeconomic disparity.

This study has several strengths. Age-standardization is critical for long-term trend analysis.^{24,39} Our findings on age-standardized net survival are consistent with the recent data of net survivals of invasive and in-situ breast cancers reported by Public Health England.⁶ Moreover, we used the most updated life tables for computing net survivals, which were levied on the recent methodological changes and advantages.¹⁷ Specifically, the updated life tables have better coding, enhancement to inclusion and cohort-selection criteria, and correction to capturing dates of death. In addition, subgroup analyses by race, histology, stage and grade help better understand trends among the strata of these variables. But future multivariable studies are needed to adjust for these variables if possible. Furthermore, this population-based, large scale study had sufficient statistical power and few biases, despite its limitations. Finally, the quasi-experimental design, although not as rigorous as randomized clinical trials, provides solid evidence on the association of trend changes in nonscreened breast cancer proportional-incidence with those in their net survivals.

This study has several limitations. First, survival analysis on the effects of cancer screening may result in lead-time and length-time biases. However, this quasi-experimental study was focused on the association of trend changes in the proportional incidence and net survivals of nonscreened breast cancers, and should be less susceptible to the biases. Moreover, given additional survival benefits of screened cancers linked to these biases, the decrease in net-survival benefits of screened cancers would be more profound should these biases be eliminated. Second, several prognostic factors of breast cancer and socioeconomic factors are not available for analysis including statuses of estrogen and progesterone receptors and patient income levels. Third, age was not analyzed as an exposure. Our reasoning is that, given age-standardized data, the age's influence in the trend analysis would be minimal if any present. Fourth, due to the minimal follow-up time of 5 years for 5-year survival, we could not analyze the trends after the publication of 2012 independent review on breast cancer screening,⁴ although no immediate post-publication changes in the uptake of breast cancer screening were identified in the U.K.⁴⁰. Finally, some cases might be misclassified histologically or clinically, although the cancer database has been widely used,^{14,15,39} and rigorously scrutinized for quality assurance.⁶

In summary, we report a downward-to-upward trend change in proportional incidence of nonscreened breast cancer among women in England in 2007. Our quasi-experimental study also shows such a trend change is associated with a steeper upward trend in age-standardized 5-year net survival of nonscreened breast cancers after 2007. The associations slightly differed by cancer characteristics and patient race. The net-survival difference of screened versus nonscreened cancers also narrowed during 1995-2011. Our findings therefore suggest decreasing survival benefits of breast cancer screening in this cohort during 2007-2016, and support reduction of breast cancer screening in some patients. Further validations are warranted.

Authors' contributions: HW, JB, and LZ designed the study, HW, KW and JB extracted the data, HW, SL and LZ analyzed the data, HW and LZ wrote the first draft of the manuscript, and all authors edited and approved the final manuscript.

No conflict of interest is declared by any of the authors.

We cannot share the data which are confidential and were obtained with review and approval from the Public Health England.

No funding was reported.

Figure Legends

Figure. Trends in proportion and age-standardized 5-year net survival of screened and nonscreened breast cancer diagnosed during 1995-2011 among women in England (followed through 2016).

The dots show individual data points, while the lines show piece-wise log-linear trends of the best-fit model which were identified using the Joinpoint program. There was a downward trend in the proportion of incident nonscreened breast cancers (Annual percentage change [APC], 95% confidence intervals [CI]= -3.5 (-4.2 to -2.8), $P<0.001$, **Red color and the right Y axis**) during the diagnosis years of 1995-2007, followed by an upward trend (APC, 95% CI=5.6 (2.2 to 9.1), $P=0.003$) afterward. The screened breast cancers had an upward trend in age-standardized 5-year net-survival (APC, 95% CI= 0.4 (1.0 to 2.9), $P=0.01$, **Orange color**), while the nonscreened breast cancer had an upward trends during the diagnosis years of 1995-2008 (APC, 95% CI=0.6 [1.0 to 3.1], $P=0.009$, **Blue color**), followed by an even steeper upward trend afterward (APC, 95% CI=7.1 [1.0 to 9.2], $P<0.001$). The jointpoint of the trends in the proportion of cancer cases and that in age-standardized 5-year net-survival were similar (2007 and 2008, respectively) among the women with nonscreened invasive breast cancer.

Bibliography

1. Autier P, Boniol M, Middleton R, et al. Advanced breast cancer incidence following population-based mammographic screening. *Ann Oncol* 2011;22:1726-35.
2. Proportion of women taking up breast screening invitations falls. 2019. (Accessed July 2, 2019, at <https://digital.nhs.uk/news-and-events/latest-news/proportion-of-women-taking-up-breast-screening-invitations-falls>.)
3. Breast Screening Programme, England 2017-18 [NS] [PAS]. Public Health England, 2019. (Accessed July 2, 2019, at <https://digital.nhs.uk/data-and-information/publications/statistical/breast-screening-programme/england-2017-18>.)
4. The benefits and harms of breast cancer screening: an independent review. *Lancet* 2012;380:1778-86.
5. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation. *Ann Intern Med* 2016;164:244-55.
6. Cancer survival in England: national estimates for patients followed up to 2017. 2019. (Accessed July 2, 2019, at <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalinengland/nationalestimatesforpatientsfollowedupto2017>.)
7. Walters S, Benitez-Majano S, Muller P, et al. Is England closing the international gap in cancer survival? *Br J Cancer* 2015;113:848-60.
8. Gotzsche PC. Mammography screening is harmful and should be abandoned. *J R Soc Med* 2015;108:341-5.
9. Myers ER, Moorman P, Gierisch JM, et al. Benefits and Harms of Breast Cancer Screening: A Systematic Review. *Jama* 2015;314:1615-34.
10. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. *Br J Cancer* 2013;108:2205-40.
11. Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L. Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. *Ann Intern Med* 2016;164:256-67.
12. Henson KE, Elliss-Brookes L, Coupland VH, et al. Data Resource Profile: National Cancer Registration Dataset in England. *Int J Epidemiol* 2019.
13. Wallington M, Saxon EB, Bomb M, et al. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. *Lancet Oncol* 2016;17:1203-16.
14. McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. *Br J Cancer* 2015;112 Suppl 1:S108-15.
15. Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. *Lancet Oncol* 2017;18:719-31.
16. Roche L, Danieli C, Belot A, et al. Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods. *Int J Cancer* 2013;132:2359-69.

17. The impact of updating cancer survival methodologies for national estimates, 2019. 2019. (Accessed July 2, 2019, at <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/theimpactofupdatingcancersurvivalmethodologiesfornationalestimates2019>.)
18. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. *Eur J Cancer* 2004;40:2307-16.
19. Breast cancer stages, types and grades. 2017. (Accessed July 2, 2019, at <https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-types-grades>.)
20. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. Lyon, France: World Health Organization; 2013.
21. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med* 2000;19:335-51.
22. Pairwise Comparison. National Cancer Institute. (Accessed Apr 23, 2018, at <https://surveillance.cancer.gov/help/joinpoint/setting-parameters/advanced-analysis-tools-tab/pairwise-comparison>.)
23. Ingram DD, Malec DJ, Makuc DM, et al. National Center for Health Statistics Guidelines for Analysis of Trends. *Vital Health Stat* 2 2018;1-71.
24. Yuan X, Song F, Zhang L. Trend analysis of diabetic mortality. *Lancet* 2019;393:1931-2.
25. Puliti D, Duffy SW, Miccinesi G, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. *J Med Screen* 2012;19 Suppl 1:42-56.
26. Ellis L, Woods LM, Esteve J, Eloranta S, Coleman MP, Rachet B. Cancer incidence, survival and mortality: explaining the concepts. *Int J Cancer* 2014;135:1774-82.
27. Jacklyn G, Howard K, Irwig L, Houssami N, Hersch J, Barratt A. Impact of extending screening mammography to older women: Information to support informed choices. *Int J Cancer* 2017;141:1540-50.
28. Bleyer A. Screening mammography: update and review of publications since our report in the New England Journal of Medicine on the magnitude of the problem in the United States. *Acad Radiol* 2015;22:949-60.
29. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. *N Engl J Med* 2012;367:1998-2005.
30. Jiang M, Hughes DR, Appleton CM, McGinty G, Duszak R, Jr. Recent trends in adherence to continuous screening for breast cancer among Medicare beneficiaries. *Prev Med* 2015;73:47-52.
31. Ryerson AB, Miller JW, Ehemann CR, Leadbetter S, White MC. Recent trends in U.S. mammography use from 2000-2006: a population-based analysis. *Prev Med* 2008;47:477-82.
32. Yang M, Bao W, Zhang X, Kang Y, Haffty B, Zhang L. Short-term and long-term clinical outcomes of uncommon types of invasive breast cancers. *Histopathology* 2017;71:874-86.
33. Carney P, O'Neill C. Income inequality in uptake of voluntary versus organised breast cancer screening: evidence from the British Household Panel Survey. *BMC Public Health* 2018;18:252.
34. Jack RH, Moller H, Robson T, Davies EA. Breast cancer screening uptake among women from different ethnic groups in London: a population-based cohort study. *BMJ Open* 2014;4:e005586.
35. Davies EA, Renshaw C, Dixon S, Moller H, Coupland VH. Socioeconomic and ethnic inequalities in screen-detected breast cancer in London. *J Public Health (Oxf)* 2013;35:607-15.
36. Renshaw C, Jack RH, Dixon S, Moller H, Davies EA. Estimating attendance for breast cancer screening in ethnic groups in London. *BMC Public Health* 2010;10:157.
37. Jack RH, Robson T, Davies EA. The varying influence of socioeconomic deprivation on breast cancer screening uptake in London. *J Public Health (Oxf)* 2016;38:330-4.

38. Maringe C, Li R, Mangtani P, Coleman MP, Rachet B. Cancer survival differences between South Asians and non-South Asians of England in 1986-2004, accounting for age at diagnosis and deprivation. *Br J Cancer* 2015;113:173-81.
39. Steel N, Ford JA, Newton JN, et al. Changes in health in the countries of the UK and 150 English Local Authority areas 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2018;392:1647-61.
40. Taylor-Phillips S, O'Sullivan E, Kearins O, Parsons H, Clarke A. The effects of a UK review of Breast Cancer Screening on Uptake: an observational before/after study. *J Med Screen* 2013;20:86-90.

Table 1. Characteristics of the screened and nonscreened breast cancers among the Women in England, 1995-2016

	Nonscreened		Screened		All		P
	N (%)	NS, %	N (%)	NS, %	N	NS, %	
Year							<0.001
1995	4665 (62.7)	77	2771 (37.3)	96	7436	84	
1996	5175 (62.4)	77	3122 (37.6)	93	8297	83	
1997	7036 (65.3)	77	3744 (34.7)	98	10780	84	
1998	6484 (61.4)	78	4071 (38.6)	100	10555	86	
1999	6156 (57.4)	79	4563 (42.6)	99	10719	88	
2000	5794 (53.8)	78	4966 (46.2)	101	10760	88	
2001	5781 (52.0)	80	5331 (48.0)	96	11112	88	
2002	5894 (50.7)	78	5726 (49.3)	100	11620	89	
2003	6585 (49.7)	79	6671 (50.3)	99	13256	89	
2004	7132 (47.8)	79	7778 (52.2)	99	14910	89	
2005	7191 (45.5)	79	8599 (54.5)	100	15790	90	
2006	8597 (46.2)	77	9996 (53.8)	101	18593	89	
2007	7907 (43.0)	81	10479 (57.0)	99	18386	91	
2008	8965 (44.4)	81	11241 (55.6)	99	20206	91	
2009	9310 (46.3)	86	10795 (53.7)	102	20105	94	
2010	12779 (53.3)	88	11202 (46.7)	101	23981	94	
2011	12991 (52.4)	95	11815 (47.6)	100	24806	97	
Race							<0.001
Black	973 (64.6)	81	533 (35.4)	89	1506	85	
Other	54387 (50.9)	76	52543 (49.1)	97	106930	86	
White	73068 (51.2)	87	69727 (48.8)	101	142795	93	
Histology							<0.001
IDC	91671 (50.1)	84	91347 (49.9)	99	183018	91	
ILC	15960 (52.6)	86	14363 (47.4)	98	30323	92	
MDLC	3867 (41.5)	86	5457 (58.5)	97	9324	92	
Other	18540 (59.1)	70	12858 (41.0)	97	31398	80	
Tumor Stage*							<0.001
Stage1	25857 (36.2)	97	45636 (63.8)	102	71493	99	
Stage2	29271 (61.7)	87	18162 (38.3)	95	47433	90	
Stage3	6119 (75.3)	68	2009 (24.7)	88	8128	73	
Stage4	4193 (85.0)	31	743 (15.1)	72	4936	38	
Tumor grade*							<0.001
Grade1	16078 (32.4)	96	33603 (67.6)	103	49681	99	
Grade2	52877 (47.1)	90	59422 (52.9)	100	112299	95	
Grade3	44455 (64.9)	75	24069 (35.1)	92	68524	81	
Total							
	13038 (51.2)	82	122870 (48.8)	99	254062	90	

NS, age-standardized 5-year net survival; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MDLC, mixed ductal and lobular carcinoma; *P*, chi-square test for the within group differences; * data were missing in some cases.

Table 2. Trends in proportion of screened and nonscreened breast cancers diagnosed during 1995-2011 among the women in England

	Screened, %				Nonscreened, %			
	1995	2011	APC (95% CI)	P	1995	2011	APC (95% CI)	P
All	37.3	57.0*	4.0 (3.1 to 5.0)		62.7	43.0*	-3.5 (-4.2 to -2.8)	
	57.0*	47.6	-5.3 (-8.2 to -2.3)		43.0*	52.4	5.6 (2.2 to 9.1)	
Race	1998							
Black	27.3	37.1	2.3 (-0.4 to 5.1)	reference	72.7	62.9	-1.8 (-3.3 to -0.3)	reference
Other	36.9	60.0#	3.4 (0.5 to 6.3)	0.985	63.1	40.0#	-4.1 (-6.6 to -1.5)	0.879
			-10.0 (-21.9 to				12.9 (-4.2 to	
	60.0#	46.8	3.6)		40.0#	53.2	33.0)	
White	41.0	52.9^	4.7 (1.9 to 7.5)	0.963	59.0	45.8*	-3.5 (-5.5 to -1.4)	0.783
	52.9^	48.2	-3.0 (-5.9 to -0.1)		45.8*	51.8	4.2 (-0.8 to 9.5)	
Histology								
IDC	39.8	57.4*	3.6 (2.6 to 4.5)	0.736	60.2	42.7*	-3.3 (-4.1 to -2.5)	0.998
	57.4*	48.5	-4.8 (-7.7 to -1.8)		42.7*	51.6	5.3 (1.7 to 9.0)	
ILC	36.9	56.8*	4.2 (3.5 to 4.9)	reference	63.1	43.2*	-3.3 (-3.9 to -2.8)	reference
	56.8*	45.5	-5.6 (-7.7 to -3.5)		43.2*	54.5	5.4 (2.9 to 8.0)	
MDLC	69.5	62.7*	1.9 (0.3 to 3.5)	0.014	30.5	35.1*	-3.6 (-5.9 to -1.3)	0.176
	62.7*	52.4	-8.4 (-17.3 to 1.5)		35.1*	47.6	9.6 (0.9 to 18.9)	
Other	27.8	50.4&	7.7 (5.9 to 9.4)	<0.001	72.2	51.0*	-4.1 (-4.9 to -3.3)	0.005
	50.4&	42.1	-2.8 (-4.3 to -1.1)		51.0*	57.9	2.9 (1.0 to 4.8)	
Tumor stage								
Stage1	49.1	27.1#	-5.2 (-6.6 to -3.7)	reference	50.9	71.9*	3.8 (2.8 to 4.9)	reference
	27.1#	31.4	5.6 (-4.9 to 17.3)		71.9*	68.6	-1.7 (-4.1 to 0.7)	
Stage2	73.3	54.4*	-3.1 (-4.1 to -2.1)	0.024	26.7	45.7^	5.9 (3.5 to 8.4)	<0.001
	54.4*	59.5	4.1 (-0.4 to 8.8)		45.7^	40.6	-3.7 (-7.5 to 0.3)	
Stage3	88.6	70.1	-1.8 (-2.5 to -1.1)	0.003	11.4	32.7^	14.5 (7.6 to 21.9)	<0.001
					32.7^	29.9	-2.5 (-9.0 to 4.4)	
Stage4	90.1	77.9	-1.0 (-1.3 to -0.7)	0.048	9.9	22.1	6.5 (4.7 to 8.4)	<0.001
Tumor Grade								
Grade1	58.0	71.5*	2.7 (2.1 to 3.3)	reference	42.0	24.9*	-5.1 (-6.2 to -3.9)	reference
	71.5*	68.4	-3.1 (-5.2 to -0.9)		24.9*	31.6	7.0 (1.1 to 13.2)	
Grade2	40.2	61.6*	4.3 (3.4 to 5.2)	0.002	59.8	38.4*	-4.3 (-5.1 to -3.5)	0.018
	61.6*	51.3	-5.2 (-7.6 to -2.7)		38.4*	48.7	6.4 (2.9 to 10.1)	
Grade3	26.1	41.5#	4.1 (3.0 to 5.1)	0.001	73.9	58.5#	-2.1 (-2.6 to -1.6)	0.001
	41.5#	33.3	-9.4 (-14.7 to -3.8)		58.5#	66.7	5.7 (1.9 to 9.5)	

IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MDLC, mixed ductal and lobular carcinoma; P, P-values of parallelism test for the within group differences (<0.05 indicates different slopes/trends compared with the reference); APC, annual percentage change; CI, confidence intervals; symbols indicate the diagnosis year corresponding to a joinpoint when two slopes/trends intercept, including & for 2004, ^ for 2006, * for 2007 and # for 2008.

Table 3. Trends in age-standardized 5-year net survival of screened and nonscreened breast cancers diagnosed during 1995-2011 among the women in England

	Screened, %				Nonscreened, %				$P_{\text{parallelism}}$ for screened vs nonscreened
	1995	2011	APC (95% CI)	P	1995	2011	APC (95% CI)	P	
All	96	100	0.1 (0.4 to 1.0)		77	81#	0.3 (0.1 to 0.6)		<0.001
					81#	95	5.7 (4.3 to 7.1)		
Race									
White	100	101	0.0 (-0.1 to 0.1)	reference	96	82#	-1.5 (-2.1 to -0.9)	reference	0.494
					82#	97	6.4 (2.7 to 10.1)		
Black	97§	90¶	0.7 (0.1 to 1.4)	0.082	51	99	2.0 (1.2 to 2.8)	0.015	0.004
Other	93	98	0.4 (0.2 to 0.7)	0.001	72	74*	0.3 (-0.4 to 1.0)	<0.001	0.004
					74*	93	5.9 (3.6 to 8.3)		
Histology									
IDC	96	101	0.3 (0.2 to 0.5)	reference	80	83#	0.2 (-0.1 to 0.4)	reference	<0.001
					83#	96	5.3 (3.8 to 6.9)		
ILC	85	101	0.3 (0.1 to 0.5)	0.626	87	82*	-0.6 (-1.5 to 0.3)	0.203	<0.001
					82*	98	4.7 (2.5 to 7.0)		
MDLC	97	101	0.3 (0.1 to 0.5)	0.89	86	76#	0.0 (-0.9 to 0.9)	0.858	0.012
					76#	99	5.1 (2.0 to 8.3)		
Other	86	106^	1.5 (0.8 to 2.1)	0.009	65	63^	0.2 (-0.6 to 0.9)	0.003	0.009
	100^	97	-2.5 (-5.0 to 0.0)		63^	86	5.2 (3.8 to 6.7)		
Staging									
Stage1	96	104£	0.2 (-0.1 to 0.6)	reference	96	100	0.3 (0.1 to 0.5)	reference	0.002
	104£	100	-2.0 (-4.7 to 0.8)						
Stage2	62	101	0.6 (0.4 to 0.9)	0.014	80	83^	0.8 (0.3 to 1.4)	0.006	0.053
					83^	99	2.9 (2.0 to 3.7)		
Stage3	NA	89§	347.0 (-67.1 to 5981.0)	<0.001	41	98	5.6 (4.4 to 6.8)	<0.001	<0.001
	89§	101	1.4 (0.5 to 2.4)						
Stage4	NA	94	5.2 (2.2 to 8.2)	<0.001	16	17*	-4.1 (-15.5 to 8.8)	<0.001	0.009
					17*	68	40.5 (11.2 to 77.6)		
Grade									
Grade1	99	106^	0.3 (0.0 to 0.6)	reference	98	97	0.1 (-0.1 to 0.3)	reference	<0.001
	106^	101	-0.8 (-1.3 to -0.4)						
Grade2	98	101	0.3 (0.2 to 0.5)	0.005	88	87#	0.1 (-0.2 to 0.4)	0.004	<0.001
					87#	98	3.7 (2.4 to 5.0)		
Grade3	87	99	0.8 (0.5 to 1.2)	<0.001	65	75#	1.1 (0.8 to 1.5)	<0.001	<0.001
					75#	94	8.0 (6.3 to 9.8)		

IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MDLC, mixed ductal and lobular carcinoma; NA, not available; *P*, *P*-values of parallelism test for the within group differences (<0.05 indicates different slopes/trends compared with the reference); APC, annual percentage change; CI, confidence intervals; symbols indicate the diagnosis year corresponding to a joinpoint when two slopes/trends intercept, including § for 1998, & for 2004, ^ for 2006, * for 2007, # for 2008, £ for 2009 and ¶ for 2010.